The

Best

Add Zone For You

User blogs

Tag search results for: "market research"
ChemAnalyst

ChemAnalyst is a subsidiary of Techsci Research, which was established in 2008, and has been providing exceptional management consulting to its clients across the globe for over a decade now. For the past four years, ChemAnalyst has been a prominent provider of Chemical commodity prices in more than 15 countries. We are a team of more than 100 Chemical Analysts who are committed to provide in-depth market insights and real-time price movement for 300+ chemical and petrochemical products. ChemAnalyst has reverberated as a preferred pricing supplier among Procurement managers and Strategy professionals worldwide. On our platform, we provide an algorithm-based subscription where users can track and compare years of historical data and prices based on grades and incoterms (CIF, CFR, FOB, & EX-Works) in just one go.




The ChemAnalyst team also assists clients with Market Analysis for over 1200 chemicals including assessing demand & supply gaps, locating verified suppliers, choosing whether to trade or manufacture, developing Procurement Strategies, monitoring imports and exports of Chemicals, and much more. The users will not only be able to analyze historical data for past years but will also get to inspect detailed forecasts for the upcoming years. With access to local field teams, the company provides high-quality, reliable market analysis data for more than 40 countries.




ChemAnalyst is your one-stop solution for all data-related needs. We at ChemAnalyst are dedicated to accommodate all of our world-class clients with their data and insights needs via our comprehensive online platform.




Company Name: ChemAnalyst


Contact Name: Imani Jex


Address:    3040 Post Oak Boulevard 18th Floor, Houston, Texas, United States, 77056  


Contact No.: +1 3322586602


Email id: sales@chemanalyst.com


Website: https://www.chemanalyst.com/


Follow LinkedIn Profile: https://www.linkedin.com/company/chemanalyst/


Follow Twitter Profile: https://twitter.com/chemanalysts


Follow Facebook Profile: https://www.facebook.com/ChemAnalysts/

Jasper Colin
In today’s climate, businesses need faster and more accurate insights that match the speed of the changing landscape. Discover market insights from JCR’s industry experts about your market and be on top of market trends, consumer behavior, and competitor strategies. We enable our clients with the actionable insights that help them explore a newer market and advice accordingly based on the data we have collected and processed in our predictive model.



Jasper Colin


Custom dashboards allow you to present your data in a way that works for your business growth. JCR's AI-enabled custom dashboard measures the impact of the emerging opportunities on the market's momentum. Catering to the ever-increasing need for real-time data to beat the competition, we empower you with knowledge so you may spearhead accurate decision-making. We provide effective data dashboards for' both B2B and B2C surveys to garner hidden actionable insights. Get in touch with us for highly functional custom dashboards



stefan

The RNA interference (RNAi) technique was discovered close to two decades ago. As of today, it is considered among the upcoming and versatile therapeutic mechanisms known to medical science. Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids. Cells use this process to silence and / or inhibit gene expression, via the targeted degradation of specific (unwanted) mRNA molecules. From an application perspective, the gene specificity of RNAi is the primary reason why it is being considered for therapy development. In theory, RNAi based therapeutics are capable of treating indications, such as age-related macular degeneration (AMD), hepatitis C and various forms of cancer, which are actually hard to treat, using conventional pharmacological options.

 

Report Link- https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

 



RNAi technology has emerged as a powerful tool to analyze various genes in a variety of organisms. This technology can be used in functional genomics as it is highly specific and can silence a particular gene from a multiple gene family. Since, RNAi depends on sequence homology, it enables the selection of unique / conserved regions of target genes for silencing.

 

One of the major challenges in this domain is related to the delivery of RNAi therapeutics. However, in recent years, several types of novel delivery systems have been developed and are being investigated for therapeutic nucleic acid delivery. The key aim in this context is to increase the efficiency of drug delivery to the target site. Examples of the various delivery systems, which are either already being used, or under evaluation, include lipid nanoparticle delivery, polypeptide delivery and conjugated delivery system. In summary, RNAi-based therapeutics are expected to soon become one of the prominent therapeutic options within mainstream healthcare.

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.htmlor email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.     Gene Therapy Market (3rd Edition), 2019-2030

2.     Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030

3.     Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030

 

 

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/


[1]Source: https://www.intechopen.com/books/functional-genomics/rnai-towards-functional-genomics-studies

[2]ONPATTRO® is the registered trademark of Alnylam Pharmaceuticals.

stefan

Several systemic disorders and localized (organ system specific) clinical conditions have been demonstrated to be a result of genetic aberration / mutation. Such disorders can theoretically be treated by correcting the abnormal gene / allele, which is responsible for coding a dysfunctional / non-functional protein. This is essentially the basis for a gene therapy. Today, there are a variety of gene-focused corrective strategies that have been developed for treating a wide range of clinical conditions that are caused due to genetic aberrations, such as adenosine deaminase severe combined immunodeficiency (ADA-SCID), β-thalassemia, biallelic RPE65 mutation-associated retinal dystrophy, critical limb ischemia, head and neck squamous cell carcinoma, melanoma, peripheral artery disease and spinal muscular atrophy. Presently, more than 10 gene therapies have already been approved; examples of recently approved gene therapies include Collategene[1] (AnGes), Zolgensma[2] (AveXis), and Zynteglo[3] (bluebirdbio). Considering that such therapies are designed to address the root cause (at the genetic level) of a disease, a number of contemporary drug / therapy development initiatives are focused on gene correction and genome editing-based therapeutic interventions. It is also worth highlighting that the growing need for treatment options to cure a clinical condition, as opposed to treating disease-related symptoms only, has created a demand for more effective gene manipulation approaches.

 

Report Link- https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Gene therapies can be classified into ex vivo and in vivo therapies. An ex vivo gene therapy involves the modification of the target gene segment (within a cell / group of cells) outside the body. In this case, allogeneic (derived from donor organisms of the same species) or autologous (derived from the patient’s own body) cells may be used. Once isolated, the cells are grown and temporarily maintained under in vitro conditions. Subsequently, the cells are transduced / transfected with an appropriate viral / non-viral vector, which carries the therapeutic gene. The modified cells are then allowed to grow and proliferate in vitro, until they reach the are a pre-specified concentration, at which they are considered to be suitable for dosing. However, ex vivo gene therapiesare efficient only if the therapeutic gene is stably incorporated inside the target site (within the genome of the target cell) and is constitutively expressed. This is dependent on the type of vector used.[4]

 

The route of administration of gene therapy depends on the purpose of the therapy and the target site.Some of the common routes of administration for genetic medicines are explained below:[5]

§  Oral:This is the easiest and the most painless method of dosing; it is done in cases where there is a daily need for intake of the therapeutic agent. Cells in the gastrointestinal (GI) tract are transfected via the oral route. The drawbacks associated with this route of administration include the epithelial barrier and the acidic pH in the stomach, which affect the potency and transduction efficiency.

§  Intravenous (IV):This is one of the preferred routes of administration for most of the gene therapies. However, they may need frequent dosing, causing widespreadbio-distribution of vectors, and leading to the development of unwanted side effects. For instance, upon intravenous injection, adenoviral vectors have been shown to exhibit liver tropism. In addition, these vectors are known to elicit undesirable innate and adaptive immune responses, resulting in the production of neutralizing antibodies, which interfere with the therapeutic effect of the product.

§  Local Administration:This route is used for the transfection of cells within a specific site / tissue / organ of interest. This can be carried out via vasculature and non-vasculature dependent routes of administration. Vasculature dependent routes involve the use of intra-arterial, intra-portal and retrograde intravenous routes. This is a highly selective method of delivering the gene medicine, but it may require cannulation, which can be painful. On the other hand, non-vasculature dependent routes involve the direct administration of naked DNA plasmids at the targeted site / organ.

 

§  Organ Surface Routes:This method of gene deliveryis generally used for intra-abdominal and intra-thoracic organs. This route enables the therapy to be targeted to diseased regions only. The key drawback of this route of administration is that it requires a laparoscopy procedure.

A gene therapycan be performed within (in situ) or outside (ex situ) the body of a host. In the case of in situ therapies, a suitable viral / non-viral vector, carrying the gene of interest, is injected directly into the part of the body that has the defective population of cells. Alternatively, for ex situ gene therapies, the blood or bone marrow is harvested from a patient and the immature cells are isolated from it. These cells are then transfected / transduced with a therapeutic gene and allowed to mature (for a specified period of time) in vitro. The transformed cells are then injected back into the bloodstream of the patient, where they move back into the bone marrow and mature rapidly. The cells bearing the desired (therapeutic) gene product grow and, in some cases, proliferate andeventually replace all defective cells (theoretically).

 

Concept of Gene Editing

The human genome refers to a complete library of genetic information and it consists of close to three billion DNA base pairs. The DNA polymers are maintained in the form of a set of 23 chromosome pairs. Each chromosome contains small sections of DNA, known as genes, which code for proteins. There are close to 20,000-25,000 human protein-coding genes, which helps in controlling synthesis of proteins. Therefore, genome is a complete set of instructions that is required by an organism to function properly. The advancements in genomics has helped the researchers to fully understand this huge amount of genomic data and its impact on fundamental biological processes and related diseases. For instance, the Human Genome Project, which was initiated in 1987, has helped the scientific community to understand the genetic basis of nearly 5,000 human disease conditions, as of today.

 

In order to effectively utilize the available genetic data for biomedical uses, the researchers have shifted their focus towards modification of human genome through multiple endonuclease technologies. This process is known as gene editing or genome engineering. It is a process of modifying a single gene or a set of genes within the genome of an organism by altering the nucleotide sequence using specialized molecular tools, such as artificially engineered nucleases or molecular scissors. A lot of genome editing techniques, such as Clustered Regularly Interspaced Palindromic Repeats (CRISPR), Zinc Finger Nuclease (ZFN) and transcription activator-like effector nucleases (TALENs) have been explored till date.

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

 

Other Recent Offerings

1.     Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

2.     CAR-T TherapiesMarket (2nd Edition), 2019-2030

3.     Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

[1]Collategene® is the registered trademark of AnGes

[2]Zolgensma® is the registered trademark of AveXis (a Novartis Company)

[3]ZYNTEGLO®is the registered trademark of bluebird bio

[4]Source: http://www.genetherapynet.com/types-of-gene-therapy.html

[5]Source: https://www.intechopen.com/books/novel-gene-therapy-approaches/targeted-gene-delivery-importance-of-administration-routes

stefan

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes.

To order this 130+ slides report, which features 80+ figures, please visit - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html

 

A picture containing text, device, clock, gauge

Description automatically generated

 

Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:

§  Digital Therapeutics Alliance (DTA)

§  Personal Connected Health (PCH) Alliance

§  Centers for Disease Control and Prevention (CDC)

§  Health Insurance Portability and Accountability Act (HIPAA)

§  National Health Service (NHS)

§  United States Food and Drug Administration (USFDA)

 

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.

§  Discovery and Preclinical Phase:  The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 

§  Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution providers, and to evaluate its potential in a real-world setting. It includes testing of the software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data.  Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 

§  Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

 

§  Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models.

 

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html

 

You may also be interested in the following titles:

1.      AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030

2.      AI-Based Clinical Trial Solution Providers Market, 2020-2030

3.      Global Handheld Ultrasound Imaging Devices Market, 2020-2030

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/
stefan

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

 

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/
stefan

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment

 

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market/267.html

 

The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugsand targets market has been analyzed across the following segments:

§  Type of molecule

§  Small Molecule

§  Biologic

 

§  Target disease indication

§  Breast Cancer

§  Colorectal Cancer

§  Fallopian Tube Cancer

§  Gastric Cancer

§  Head and Neck Cancer

§  Lung Cancer

§  Ovarian Cancer

§  Peritoneal Cancer

§  Others

 

§  Type of synlet target

§  APE1 / Ref-1

§  Chk1

§  GLS1

§  PARP

§  Pol θ

§  PP2A

§  Wee1

 

§  Route of administration 

§  Oral

§  Intravenous

 

§  Key geographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the World

 

The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/
stefan

To order this 330+ page report, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Key Inclusions

§  A detailed assessment of the current market landscape of targeted protein degradation-basedtherapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted proteindegraders.

§  Elaborate profiles of key players that are engaged in the development of targeted protein degraders(shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.

§  Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

§  A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

§  An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

§  A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.

§  An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.

§  An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

You may also be interested in the following titles:

1.   DNA-Encoded Libraries: Platforms and Services Market

2.   Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030

3.   The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

 

stefan

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Key Market Insights

§  More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts

§  The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes

§  Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain

§  Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development

§  A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts

§  Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs

§  Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014

§  The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies

§  Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs

§  As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeuticareas and various global regions

 

For more information please visit:

https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/
Pages: 1 2 3 4 5 ... » »»

Show Your Work Here .Whatsapp 9301837771

Alexa Global Rank 99000

google ranking checker website hit counter

Sales

Manager